<SEC-DOCUMENT>0001437749-13-012917.txt : 20131010
<SEC-HEADER>0001437749-13-012917.hdr.sgml : 20131010
<ACCEPTANCE-DATETIME>20131010060239
ACCESSION NUMBER:		0001437749-13-012917
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20131009
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20131010
DATE AS OF CHANGE:		20131010

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GeoVax Labs, Inc.
		CENTRAL INDEX KEY:			0000832489
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				870455038
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-52091
		FILM NUMBER:		131144503

	BUSINESS ADDRESS:	
		STREET 1:		1900 LAKE PARK DRIVE
		STREET 2:		SUITE 380
		CITY:			SMYRNA
		STATE:			2Q
		ZIP:			30080
		BUSINESS PHONE:		678-384-7220

	MAIL ADDRESS:	
		STREET 1:		1900 LAKE PARK DRIVE
		STREET 2:		SUITE 380
		CITY:			SMYRNA
		STATE:			2Q
		ZIP:			30080

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Geovax Labs, Inc.
		DATE OF NAME CHANGE:	20061002

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DAUPHIN TECHNOLOGY INC
		DATE OF NAME CHANGE:	19940826

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SUCCESSO INC
		DATE OF NAME CHANGE:	19910410
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>govx20131008_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD><TITLE>govx20131008_8k.htm</TITLE>
<!-- Created by RDG HTML Converter -->
</HEAD>
<BODY style="FONT-FAMILY: Times New Roman; MARGIN-LEFT: 10px; FONT-SIZE: 10pt; MARGIN-RIGHT: 10px">
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA3><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 18px"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA4><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>WASHINGTON, D.C. 20549 </B></FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA5><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA6><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">
<HR style="BORDER-BOTTOM: medium none; TEXT-ALIGN: center; BORDER-LEFT: medium none; BACKGROUND-COLOR: #000000; WIDTH: 21%; COLOR: #000000; BORDER-TOP: medium none; BORDER-RIGHT: medium none">
</FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA7><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B></B></FONT></P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA9><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 18px"><B>FORM 8-K </B></FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA10><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA11><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>CURRENT REPORT </B></FONT></P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA12><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>Pursuant to Section 13 or 15(d) of the </B></FONT></P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA13><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>Securities Exchange Act of 1934 </B></FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA14><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA15><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>Date of report (Date of earliest event reported): October 9, 2013</B></FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA16><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA17><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">
<HR style="BORDER-BOTTOM: medium none; TEXT-ALIGN: center; BORDER-LEFT: medium none; BACKGROUND-COLOR: #000000; WIDTH: 21%; COLOR: #000000; BORDER-TOP: medium none; BORDER-RIGHT: medium none">
</FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA18><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA19><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 18px"><B>GEOVAX LABS, INC.</B></FONT></P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA20><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>(Exact name of registrant as specified in Charter) </B></FONT></P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA21><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>&nbsp;</B></FONT><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"></FONT></P>
<TABLE style="TEXT-INDENT: 0px; WIDTH: 100%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id=TBL35  border=0 cellSpacing=0 cellPadding=0>

<TR>
<TD style="WIDTH: 31.3%; VERTICAL-ALIGN: top">
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA24><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>Delaware</B></FONT></P></TD>
<TD style="WIDTH: 3%; VERTICAL-ALIGN: bottom">
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA25><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P></TD>
<TD style="WIDTH: 31.3%; VERTICAL-ALIGN: top">
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA26><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>000-52091</B></FONT></P></TD>
<TD style="WIDTH: 3%; VERTICAL-ALIGN: bottom">
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA27><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P></TD>
<TD style="WIDTH: 31.3%; VERTICAL-ALIGN: top">
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA28><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>87-0455038</B></FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 31.3%; VERTICAL-ALIGN: top">
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA29><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>(State or other jurisdiction of</B></FONT></P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA30><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>incorporation or organization)</B></FONT></P></TD>
<TD style="WIDTH: 3%; VERTICAL-ALIGN: bottom">
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA31><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P></TD>
<TD style="WIDTH: 31.3%; VERTICAL-ALIGN: top">
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA32><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>(Commission File No.)</B></FONT></P></TD>
<TD style="WIDTH: 3%; VERTICAL-ALIGN: bottom">
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA33><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P></TD>
<TD style="WIDTH: 31.3%; VERTICAL-ALIGN: top">
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA34><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>(IRS Employee Identification No.)</B></FONT></P></TD></TR></TABLE>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA36><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA37><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>1900 Lake Park Drive</B></FONT></P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA38><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>Suite 380</B></FONT></P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA39><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>Smyrna, Georgia 30080</B></FONT></P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA40><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>(Address of Principal Executive Offices) </B></FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA41><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA42><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>(678) 384-7220</B></FONT></P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA43><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>(Issuer Telephone number) </B></FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA44><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA45><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA46><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction A.2 below).</FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA47><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA48><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA49><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA50><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR240.14a-12)</FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA51><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA52><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).</FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA53><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA54><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">[ ] Pre-commencement communications pursuant to Rule 13e-4&#169; under the Exchange Act (17 CFR 240.13(e)-4(c))</FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt"><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"></FONT>&nbsp;</P>
<DIV style="WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" id=PGBK56 >
<DIV style="TEXT-ALIGN: center; WIDTH: 100%" id=PGFTR56 >&nbsp;</DIV>
<DIV style="TEXT-ALIGN: center; WIDTH: 100%; FONT-SIZE: 10pt" id=PGNUM56 >&nbsp;</DIV>
<HR style="PAGE-BREAK-AFTER: always; WIDTH: 100%; HEIGHT: 2px; COLOR: #000000" noShade>

<DIV style="TEXT-ALIGN: left; WIDTH: 100%" id=PGHDR56 >&nbsp;</DIV></DIV>
<P style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px" id=PARA56.2>&nbsp;</P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA57><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">This Form 8-K and other reports filed by GeoVax Labs, Inc. (the &#8220;registrant&#8221;) from time to time with the Securities and Exchange Commission (collectively the &#8220;Filings&#8221;) contain forward looking statements and information that are based upon beliefs of, and information currently available to, the registrant's management as well as estimates and assumptions made by the registrant's management. When used in the Filings the words &#8220;anticipate&#8221;, &#8220;believe&#8221;, &#8220;estimate&#8221;, &#8220;expect&#8221;, &#8220;future&#8221;, &#8220;intend&#8221;, &#8220;plan&#8221; or the negative if these terms and similar expressions as they relate to the registrant or the registrant's management identify forward looking statements. Such statements reflect the current view of the registrant with respect to future events and are subject to risks, uncertainties, assumptions and other factors relating to the registrant's industry, operations and results of operations and any businesses that may be acquired by the registrant. Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned.</FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA58><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA59><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>Item 8.01&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other Events</B></FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA60><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 72pt; MARGIN: 0pt" id=PARA61><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">On October 9, 2013 we issued a press release reporting the presentation of clinical data at the 2013 AIDS Vaccine Meeting in Barcelona, Spain. A copy of the press release is attached to this Current Report.</FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA62><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA63><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>Item 9.01&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Financial Statements and Exhibits</B></FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA64><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 72pt; MARGIN: 0pt" id=PARA65><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Exhibit 99.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Press Release</FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: -63pt; MARGIN: 0pt 0pt 0pt 63pt" id=PARA66><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA67><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>SIGNATURES</B></FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA68><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 72pt; MARGIN: 0pt" id=PARA69><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Current Report to be signed on its behalf by the undersigned hereunto duly authorized.</FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA70><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA71><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Dated: October 10, 2013</FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA72><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;
<TABLE style="TEXT-INDENT: 0px; WIDTH: 100%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"  cellSpacing=0 cellPadding=0>

<TR>
<TD style="WIDTH: 50%">
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id=PARA82>&nbsp;</P></TD>
<TD style="WIDTH: 50%">
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id=PARA83><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">GEOVAX LABS, INC.</FONT></P>
<P style="LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id=PARA74><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id=PARA75><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id=PARA76><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id=PARA77><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">By:<U>&nbsp;&nbsp;&nbsp;/s/ Mark W. Reynolds&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></FONT></P>
<P style="LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id=PARA78><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mark W. Reynolds </FONT></P>
<P style="LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id=PARA79><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Chief Financial Officer</FONT><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"></FONT></P></TD></TR>
<TR>
<TD>
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id=PARA84>&nbsp;</P></TD>
<TD>
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id=PARA85>&nbsp;</P></TD></TR></TABLE></FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA81><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P></BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML><HEAD><TITLE>ex99-1.htm</TITLE>
<!-- Created by RDG HTML Converter -->
</HEAD>
<BODY style="FONT-FAMILY: Times New Roman; MARGIN-LEFT: 10px; FONT-SIZE: 10pt; MARGIN-RIGHT: 10px">
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id=PARA2>&nbsp;</P>
<P style="TEXT-ALIGN: right; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt">&nbsp;<B>Exhibit 99.1</B></P>
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt">&nbsp;</P>
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt">&nbsp;</P>
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt"><IMG src="govx.jpg"></P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA1><FONT style="FONT-FAMILY: ; FONT-SIZE: 14pt"><FONT style="FONT-FAMILY: ; FONT-SIZE: 14pt"><FONT style="FONT-SIZE: 12pt"><B>GeoVax DNA/MVA Vaccine Elicits</B></FONT></FONT><FONT style="FONT-FAMILY: ; FONT-SIZE: 14pt"></FONT></FONT></P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA3><FONT style="FONT-FAMILY: ; FONT-SIZE: 14pt"><FONT style="FONT-FAMILY: ; FONT-SIZE: 14pt"><FONT style="FONT-SIZE: 12pt"><B>Sustained Antibody Responses to HIV</B></FONT></FONT><FONT style="FONT-FAMILY: ; FONT-SIZE: 14pt"></FONT></FONT></P>
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id=PARA5>&nbsp;</P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA4><FONT style="FONT-FAMILY: ; FONT-SIZE: 12pt"><FONT style="FONT-FAMILY: ; FONT-SIZE: 12pt"><B><I>New Clinical Data from HVTN 205, a Phase 2a Trial of GeoVax&#8217;s</I></B></FONT></FONT><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 11px"><B></B></FONT></P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA6><FONT style="FONT-FAMILY: ; FONT-SIZE: 12pt"><FONT style="FONT-FAMILY: ; FONT-SIZE: 12pt"><B><I>Preventive HIV Vaccine, Presented at 2013 AIDS Vaccine Meeting</I></B></FONT></FONT><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 11px"><B></B></FONT></P>
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id=PARA8>&nbsp;</P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA7><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>Atlanta, GA, October 9, 2013 GeoVax Labs, Inc. (OTCQB: GOVX</B>), a biotechnology company developing vaccines to prevent and treat HIV/AIDS, today presented additional results from HVTN 205, a multicenter, randomized Phase 2a trial evaluating the safety and immunogenicity of the Company&#8217;s first generation preventive HIV vaccine, at the 2013 AIDS Vaccine Meeting in Barcelona, Spain. At 6 months post-vaccination, patient antibody levels had declined less than 3-fold, indicating significant durability of the antibody response.</FONT></P>
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id=PARA9>&nbsp;</P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA10><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">HVTN 205 was designed to evaluate the safety and immunogenicity of a prime-boost vaccine regimen of GeoVax&#8217;s DNA vaccine and MVA (modified vaccinia Ankara) vaccine in healthy, HIV-uninfected adults. The trial extended the safety and immunogenicity results obtained in the Company&#8217;s earlier Phase 1 trials (HVTN 065 and HVTN 045). In HVTN 205, 299 participants were randomly assigned to three study arms: 149 participants received two injections of GeoVax&#8217;s DNA vaccine followed by two injections of the company&#8217;s MVA vaccine (DDMM arm), 75 participants received three MVA injections followed by one placebo injection (MMM arm), and 75 participants received four injections of placebo. After the final vaccination, antibody responses against the HIV Envelope protein (Env), the target for protective antibody, were detected in 93.2% of the DDMM arm (the vaccination regimen selected for further clinical study). At six months after final vaccination (the latest time point tested), gp140 IgG antibody response titers in the DDMM arm had declined by less than 3-fold, with response rates only declining from 100% to 84%, indicating significant durability of the antibody response. Additionally, HVTN 205 also showed that the antibody responses after vaccination had high affinity binding, a characteristic which has been associated with prevention of HIV infection in preclinical models.</FONT></P>
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id=PARA11>&nbsp;</P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA12><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&#8220;We are very pleased with the durability of our antibody responses,&#8221; said Dr. Harriet Robinson, Chief Scientific Officer at GeoVax. &#8220;We are also encouraged that our vaccine is eliciting tightly binding Ab in humans. The key to a successful preventive vaccine is the antibody response, which needs to be both sustained and capable of high affinity binding.&#8221;</FONT></P>
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id=PARA13>&nbsp;</P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA14><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">HVTN 205 was conducted by the HIV Vaccine Trials Network (HVTN), with financial support from the National Institute of Allergy and Infectious Disease (NIAID) of the National Institutes of Health (NIH). The HVTN is currently conducting a Phase 1 trial (HVTN 094) of GeoVax&#8217;s second-generation DNA/MVA vaccine, which co-expresses an adjuvant (GM-CSF) in the DNA vaccine. The dosing regimen during this trial follows a vaccination schedule similar to the DDMM arm of HVTN 205. In the preclinical model, co-expressed GM-CSF has enhanced antibody responses and increased prevention of infection by serial rectal challenges. Pending the success of HVTN 094, GeoVax expects to begin a Phase 2a trial of the GM-CSF-adjuvanted vaccine in 2014.</FONT></P>
<P style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px" id=PARA33.1>&nbsp;</P>
<P style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px">&nbsp;</P>
<P style="TEXT-ALIGN: center; MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px">MORE</P>
<DIV style="WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" id=PGBK33 >
<DIV style="TEXT-ALIGN: center; WIDTH: 100%" id=PGFTR33 >&nbsp;</DIV>
<DIV style="TEXT-ALIGN: center; WIDTH: 100%; FONT-SIZE: 10pt" id=PGNUM33 >&nbsp;</DIV>
<HR style="PAGE-BREAK-AFTER: always; WIDTH: 100%; HEIGHT: 2px; COLOR: #000000" noShade>

<DIV style="TEXT-ALIGN: left; WIDTH: 100%" id=PGHDR33 >&nbsp;</DIV></DIV>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt"><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B></B></FONT>&nbsp;</P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt"><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>About GeoVax&#8217;s Technology</B></FONT></P>
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id=PARA15>&nbsp;</P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA16><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">GeoVax&#8217;s unique, two component vaccine, a recombinant DNA and a recombinant modified vaccinia Ankara (MVA), is designed to stimulate both anti-HIV T cell and anti-HIV antibody immune responses. GeoVax&#8217;s DNA and MVA vaccines are used in a prime/boost protocol in which priming is done with the DNA and boosting with the MVA. Both the DNA and MVA express the three major proteins of the AIDS virus: Gag, Pol, and Env, and produce non-infectious virus-like-particles. GeoVax&#8217;s vaccines are unique in expressing virus-like particles that display the trimeric membrane bound form of the HIV-1 envelope glycoprotein. In GeoVax&#8217;s second generation vaccine, the DNA prime co-expresses GM-CSF with the virus-like particles, delivering a normal human protein that stimulates immune responses to the site of vaccination. All preventative Phase 1 human clinical trials conducted to date tested various combinations and doses of the DNA and MVA vaccines, their ability to raise anti-HIV humoral (antibody) and cellular (cytotoxic T cell) immune responses, as well as the vaccines&#8217; safety. For more information, please visit <U>www.geovax.com</U></FONT><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">.</FONT></P>
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id=PARA18>&nbsp;</P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA17><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA19><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>About HIV/AIDS </B></FONT></P>
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id=PARA20>&nbsp;</P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA21><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">AIDS is an epidemic that can affect anyone, regardless of race, gender, age or sexual orientation. 33 million people are currently infected globally; it is estimated that there will be 2.5 million new infections this year. Since the beginning of the epidemic, more than a million people in the U.S. have contracted the virus. More than a quarter of new US infections are in youths aged 13 to 24; and of those, 60 percent do not know they are infected. Globally, HIV is the top killer among women of reproductive age. HIV is a worldwide disease with different subtypes (or clades) of the virus predominating in different regions of the world. Clade B is the predominant subtype in North America. Globally, most infections involve subtypes AG, B and C. GeoVax vaccines are currently designed to function against clade B. </FONT></P>
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id=PARA22>&nbsp;</P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA23><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B><I>Forward-Looking Statements</I></B></FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA24><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><I>Certain statements in this document are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax can develop and manufacture its vaccines with the desired characteristics in a timely manner, GeoVax's vaccines will be safe for human use, GeoVax's vaccines will effectively prevent AIDS in humans, vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete vaccine development, there is development of competitive products that may be more effective or easier to use than GeoVax's products, GeoVax will be able to enter into favorable manufacturing and distribution.</I></FONT></P>
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id=PARA25>&nbsp;</P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA26><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><I>&nbsp;</I></FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA27><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B><I>Contact:</I></B></FONT></P>
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id=PARA29>&nbsp;</P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA28><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><I>Susanna Mesa</I></FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA30><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><I>The Trout Group</I></FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA31><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><I>646-378-2933</I></FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA32><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><I>smesa@troutgroup.com</I></FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt"><EM></EM>&nbsp;</P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt"><EM></EM>&nbsp;</P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt"><EM>###</EM></P></BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>govx.jpg
<TEXT>
begin 644 govx.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``(!`0(!`0("`@("`@("`P4#`P,#
M`P8$!`,%!P8'!P<&!P<("0L)"`@*"`<'"@T*"@L,#`P,!PD.#PT,#@L,#`S_
MVP!#`0("`@,#`P8#`P8,"`<(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`S_P``1"`!7`.(#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#]_****`"B
MBB@`HHHH`**;*XBB9B0`H))/05Y9\1?VW/@]\(KF2#Q/\4_AQH%S"2&M[[Q)
M:0W&1V$9DW$\'C&>.E7"G4F[4XMOR5S.K6ITUS5))+S=CU6BOD;QG_P72_99
M\%32PS?%2SU*:('":5H^H:@'//`>&!H^W4L!R,D#FO,?%/\`P<H_L\:#N^P:
M=\3/$*KT:PT&*,'_`,")XB/QQUKU*7#^:5/@P\__``%_J>56XARRE\>(A_X$
MC]!\BBOR\\1?\'1WPOM&8Z7\,_'URG\/VZZL+-B?<+-(!V[FN)UG_@ZNTB%F
M6Q^"\T_.!]I\91VY(_X!:/C\\>]=\>#LZDKK#OYM+\V<,N,\E3M[=?)2?Y)G
MZ\T5^05M_P`'0/B'6A_Q+OV=9+D$?*T?C"><?7Y-.Y'Z>]7(?^#D/XE7/,7[
M,6I.IY!75[]@1ZY&GUH^"<X2O*DE_P!OP_\`DC/_`%VRA_#4;_[=E_D?KC17
MY*Q_\'('Q%A&;C]EO6W'^QK5^F?STTTI_P"#FW6]*R=3_9MUJSC'+$>*9CCV
M^?3DQ^>/>H_U.S=_#23])0_^2*7&F4?:J->L9?Y'ZTT5^4FD?\'4?@<2A-6^
M$WBFP?(#"#6;:<KZ_?6/WKN/#_\`P<^?`;5'1+OPK\4]/D.-Q_L^PN(Q^*7A
M;'_`:SGPCG,=\._P?Y,UAQ?D\MJZ^=U^:/T3\2>)K'PGIDEYJ=Y9Z?918\RY
MNITABBR<#<S$`9)`'J:J^%/'FB^.+:6;1=7TG6(K:012O8WB7"Q.0#M8H3AL
M$'![$5^,G_!;S]L1_P#@H1XY^"'PD^&<=Y<VGB6WL=?2SOHS;2W%]JA6+38Y
MD)S&4MI3.0V,1WD;'@$#[]_8S_:V_96^!GP.\-?#KP/\8?AC!IOAJU2SA^U:
MS;6$U_+QYMPPD*;Y)I2TC,H(9G)'!J<7P]5H8&EBI<SG.[Y5%^['9-OS>RMJ
M5A>(:5?'5,-&RA"RYG)>]+>R7EUUT/KBBLOPOXNTSQII4=]I&H:?JUE(1LN;
M.X2>%^`>&0D'K6I7SS36^A]!&2:N@HHHH*"BBB@`HHHH`****`"BBO%OVVOV
MZ/A_^P9\+3XF\>:@T7VUG@TS2[4+)J&LS!23%!&2`<#!9V*H@8;F&0#K0HU*
MU2-&C%RD]$D8UZ].C3=6K)1BMV^A[0WW3]*\`_::_P""G/P/_9&>>S\;>/\`
M1X-=@&U]$TYCJ6J*V,A6MX`SQYQPT@1?>OQ9_;9_X+@_&K]KJ[OM*TS59?AI
MX-GS&FCZ!=,MU,A_Y^KU=LLC8)#+'Y<9!P4.,GQ;]D+]@_XF?MS>,I=)^''A
MH7D%K-LU'5[MC;Z3I)89'G3E2"V"I\M`\I!W;""37Z-@O#Y4J7UK.*WLXKHK
M?C+:_I?U/S;'^(+JUOJN4474D]F[V]4NJ\W;T/T=^/'_``="Z?%]HMOAA\+;
MF]4@K#J7BG4$MER,_-]EM]Y89[&=&QVSQ7ROXG_X+6_M9_M1^*#HGA;7KO3[
MN\^YHW@7PT))L9P"#LGNAU`RL@SCI7WG^R5_P;=?"WX9V]KJOQ1U?4OB5K8(
MD>QCFDL-&B/7:$1_.F"YQEY`K]3$,E:^_?A?\&O"?P.\+PZ+X,\-:#X3T>$@
MK9Z/I\5E!GU*Q@`GCD]?>L*V=\.X'W<!A?:R7VI[?C?]#>CDO$6/7-C\5[*+
M^S#?\+?FS\(="_X)0?MH?MHF*Z\91>)XM.N<,EQ\0_%LQ1,GC-NSS7"8)/#0
MJ0.`#TKW3X3_`/!K3K,PAF\:?%O2]-`.)+/P_P"'WN"2>.+B=TP,_P#3`Y'I
M7T__`,%;O^"S.G?L(F/P7X+LK'Q-\4[R!+B6*XW26/AV&09C>Y$9#22R#F.!
M64E2'8JNP2?(GAO_`()\?MW?M[Z:OB?QY\2-9\&6FHA9(M/U_7KG2SMQ\K+I
MEA'Y<'!QB58I./F4GD^G1SC-Z^'6(J5J>$HOX?=U?^%6;?X'F5LGRBCB'AJ=
M&IBZT?B][1?XGHD_O/J3X>?\&U'P`\*&*36]4^(WB^08,B7NLQVD+=,A1:PQ
M.JGGC>2,GGI7LO@[_@BS^S!X&9#;?"'P_?,F#G5KBZU3=C'47$K@].F,=>.3
M7P8G_!OY^TW`%,?QWT8%3P!K^LJ/T2OL#_@DK^QG\:_V)]<\>^'OBAXV7QOX
M<U6/3;W0+F/5;F^CM;A3=)=QXN0)8R5%H<#*$+P0P:O`S:O5]A*K3S1U6OLK
MGC?TZ?(]_*L-15:-*>6*FG]I\LK>O7YGT!X5_89^"W@B4'1OA#\+]((QAK/P
MI8PN3ZEA%DG@?E7HN@>#M+\*1>7IFFZ?IT>,;;:V2$`>@"@5JT5\7.M5G\<F
M_5GVU/#TZ?P12]$`X%%%(>AK,V%H/(KYS_X*<?LBR?M@?LI>)=&TF>[LO&VD
MVKZEX9N[*ZDM;A;V-698/,1E/ES@-"P.1B3?@LB$?,W_``;F_MJ:E\>/V>M=
M^'?BC5=0U7Q-\/KQ+BTGU*=I;NXTNZ+,@9I&+N89UECZX1&@4=!7JT<K=;+Y
MXZE*_LVE*-M4GL[WU^X\BKFOLLPA@:D;<Z;C*^C:W6VC^9^CU[I\6H6SQ7$<
M4\3C!21`RG\#Q7EGQQ^#7P@T7X>Z_P")?&_@/P%>:'X>TZXU34Y]0T"UN1';
M0QO)*Y#H<X16/O7K+#*FOS=_X.3?VJT^$G[*>D_#73[@IJ_Q/NR;T*V&BTNR
M=)IN0<@R3-;QXQ\Z&8<XQ4Y-@JN,QU+"TFTY-+1].K^2*SK&4L)@ZF*JI/E3
M>O?HOFSYM_X(J?!>7_@H#^WE\3OC?XSTPIH>FQ3I;V2EH8[>YU&)[>&UA=`"
M([73TDC&"K)NMR"",U]F^._^#=K]F/Q=9NFF>'O%'A%V4@/I'B*Y?8>>52Z:
M=%Z]`N..G7/I/_!(/]DB3]CG]A'P=X=U"W%KXFUI#XC\0KL*.+Z["N8F'9H8
MEA@/;]P*^GZ]C.N(L2\PG/`U90A&T8V;7NQT7ZGCY+PYAO[/A#&TXSG+WI-I
M/66K_0_*SQ3_`,&PN@^&]4_M/X9_&KQIX2OXLM')J%A%=R#T'FVSVKKSC)&?
MI61+^P]_P4,_9;\Q_`?QKM/B)I\#8BM-0UG[;=R*,''EZK"T:#``^2<8SQ@Y
M)_6JBL8\6YA)<N)<:J[3A&7Z7_$W?"67Q?-AU*D^\)27ZM?@?D;/_P`%IOVH
M_P!CJ;ROC[^SZD^EVVV.75[.TNM)ASG;O-TOVFSD/3"H4!+#I7TC^SC_`,'`
MG[/'QW:WL]6US4?AOJTQ51#XGMUBM6)`R1>0M);JHSUE>,GTZU]OSQ":%T8`
MJRE2",\5\M?M-_\`!&_]GW]J*WN[G5O`UGX<URX#,=9\,@:7>;SG+LL:^3,W
M/6:.2K6/R;$Z8K#ND_YJ;_\`;97_``9E++\YPVN&Q"JK^6HM?_`H_JCZ6\,>
M)+#QCH5MJFE7]GJ>FWR++;7=I,LT%PAZ,CJ2K*?4'%:-?C)X[_X)8_M0?\$L
M]<N_%W[.'CO6/&GAE)3=7.BVZA;MT"D'[1IK9M[X[?E\R$"?^Y&#R/I?_@F3
M_P`%U/#'[7>N6'@/XB6%KX"^)5S+]FL]K%=+U^8'!CA+DM!<;LC[/(Q+'A'=
MLJN6+X<DJ#Q>7U%6I+>VDH_XH[KUU-,'Q&G76$Q]-T:KVOK&7^&6S]#]!**0
M$,`>QI:^</IPHHHH`;+_`*MLYQ@].M?S4_\`!7;]HC7?VA_^"@WQ+FUF65;/
MPCK=WX5T>S+'R[*TL9V@.U>@,LL;SD]291V5`O\`2M*N^)ADKD$9':OQP_X+
MM_\`!(_Q!-\2]8^.?PUTF?7]-UI5NO%VC6<?F7NGW"*%_M""(<R0NJKYJJ-Z
M.#)AU=S%]SX?8["X;,VL39.4;1;Z._ZK0^#\0\#BL3EB^K7:B[R2W:_X&Y\(
M?\$Z_P!CRX_;K_:T\,?#Q+B>PTN[,NHZU>P@-)9Z?;[6F9`<X=R\<2,055YD
M)#`%3_2K\%O@QX7_`&>OAKI/@[P9HMCX>\-:'"(+*QM4VH@SDLQ.6=V.69W)
M=V+,Q+$D_P`ZW_!'W]L32/V*OVW?#GC'Q!,L/A/7+.?P_K-X/F%E:W!1UN/]
MI4GAA+[<_('(SC!_I)T?5;?7=-@O+2:*YM+I%F@GB8/',A`*NK#AE((((X(.
M17H^)=;%?7*=*=_9<JY>U^OS/.\-*.%6#J5(V]KS-2[I:6^1;K'^(?C&S^'7
MP_USQ!J)<:?H6GW&HW13[PBAC:1\>^U36Q7*?'CX>O\`%OX'>,_"D<@BD\3Z
M%?:2KDX"&>W>('/MOK\YI*+G%3VNK^A^DUG)0DX;V=O4_(/_`((+_`\_ML?M
ME?$/]H/XBI!K.J^']02_LHY?WL"ZQ?/),9$#9P+6)`L0_@$B,,%%Q^QGC+Q_
MHGPYT@WVO:MI6B6`8(;K4+N.U@#'HI>0@;C@X&><&OR<_P"#7_XN6_AV^^*W
MPMU2+^S?$IFM]?CLY@$E(B_T6\0KV,4GD!O>4_W37V!_P5`_X)BG_@I5K7P[
ML;_QC/X4\.^$EU.XNDM[074UY<SBU6#:K,(U"*DY+LK,-RJN-Y-?8\4*%3/'
M1Q<O9THJ*32NE'E5K+2]_P!3XOA>4Z>2*OA8<]5N3:;2;ES:W?2Q[O\`\-<?
M"W_HI/P_S_V,=E_\<KHO!GQ1\.?$ZQFN?#6O:+XA@MY/)EETR_ANTB?&[:S1
ML0&Q@X/..U?F0/\`@U=\&$X/Q>\4$'K_`,2.S_QKY,_X)B_%/5?V0X/VMM2\
M/WMPFH>&_`MY!97"#8%NX[];6VN63E2\;3%QG./F&<$U,>&LOQ6'J5,NQ#G*
M'+HX6^)V74JIQ)CL+7ITLQPZA&?-JIW^%7>R['Z&?M[?\%_O`'[)?C^]\%>$
M=`N_B5XQTJ86>HK#>K::7IEQR#`TX21I9U;`9(T*@Y5I$92!XQ\/_P#@YFG\
M.^-+33OBE\$]4\,Z?<XD-SI6HNUU%'G[PM;F&+S%&1DK(."<!CQ73_\`!N#^
MQCX6TK]GR7XTZG9Q:MXVUW4[JRT^\N0)I-)LX6$;"/=G;--)YK/(/F*,BYX8
MMU7[?W_!5']DKXN:=XS^#WQ$'B+Q);Z?//IES=Z=H+7*:;?1Y0S6LY((EA?(
M#H",AA\P)![X8++88F66TL).M[/2<U*5T^K45I9/H<$L;F<\-',JN+C14]80
M<5RVZ)R>MVM^Q]V_!WXR>&OV@OA?I/C+P=JUKKWAS7K?[18WMOD+,N2"&5@&
M1U8,K(X#(RLK`,"!\(_MM?\`!P[X$_9[^(MSX.^'GABY^*'B&PN38W=W%?BS
MTJ&=25:*.54D>YD5N"J($SD"0D$#X4_X)W_M>>*?@;_P3)_:PTG1=3N%32K7
M1KC29TS"^G3:O=-I=S/$0<QMY?E.N#\KQ9ZFONW_`(-W_P!C?PC\//V.]#^+
M)TZTO/&_CN6\9=1FB5Y=*LH;J6UBM;<G/EJRQ;Y",,[288L(TQSXCA_!Y4Z^
M(QR=2,9*$(WMS-Q4O>:U22>J74UP^?XS-(T*&!:IRE%SG*U^5)N/NIZ-MKKT
M//\`X-_\'+ME!X_M]"^+WPHU3P)!,5W:CIMU)=26BNV`\EE+#',8QR2T9=CT
M5&.:\%^-WQ+L?^"4W_!7C2_C%X0DM]5^#_Q8M$\0QSV+>=:WND:C(CWZPF/A
MS#<)]JC0#`7[.HX)K]7_`/@H'^Q)X4_;H_9XUOPKXCL+1]1BLYYM"U-HQ]HT
M:]"9BFC?J%W!0Z9VR)E6&*_%7]F#X.Z_^W=_P2=\?Z186\VI^)/@%K8\5^'@
M[,9'TS48)'U'3XNO!:VDN0@&6E54!&_CU<AGEM:G/$48>RA*U.K'F;C:?PR5
M^TNAYN=PS.C4AAZM3VLU>I2E9*5X:RB[=X]3^@^RO(]5L5N+>1)X9EW12QL&
M252`0RGH0?7O7XD>)M<T[_@J+_P7)U'5]5O;%/A'\(C)=7MW=S(+*/1=%<M)
M*[D[##<7SNQ<D9AFSDA#7IO[._\`P5G'@S_@A1KL_P#:AB^(_@8+\.]*=9?]
M)+7$9&GW:=2?*LO,?<W+MITO4\5\>:[\,-5_9:_X([Z9XB,,NGWW[0OBF*VN
M&5,8T#2XIG@A`(RJSW8,Y8'$D:0#!!R(X<R*I@ZM=5':<I>Q@_764EZ0U7W&
MG$.?4\92HNDKP4?;37II&/SG9,^X_CK_`,'*UO=?$.;P_P#!/X5ZCX_CB+&/
M4[YY[9K]4(S)!911/-Y)R"'E9&`(S&,BN8M_^#F;53X)UVPUCX7VGACQYI*A
MK6WN;FYN;#4&!7S+:5-L<]G*5;<C%95XP=N[<OW;_P`$O/V.O"G['O[(_A/3
M-"LK1-;U[2[75-?U-$4SZI>2Q"1BT@`9HT,A2-2<*@'<LS>/_P#!??\`9`\+
M_&S]BSQ-X^FL;2U\;_#FTCU'3M65`DTELLH$]I(W62-HY)"JG[LFTKC+;O/P
MN(R"ICH8%X9N#DH\[F^9ZVNUM9_D>CB:&?0P4L;'$I347+D45RK2]D][I&_\
M`_V^/BI^V-^P%;_%OX8^!_"\GC*UN+NVOO"VJ74K1ZBUL^&%I<H5*LZX98Y4
M(W,8RZX#M0_X)4?\%BK']OW5]>\'^*/#]KX(^(VCM)<Q:;',[PZG:(0LC1^8
M!(D\,AV2PN,@%6!/[Q8LC_@W%4M_P39A4$`GQ1JPR1D?ZQ*^=_\`@NU^R!+^
MR%\9/#?[5'PNU:V\*ZU+KT"ZK:PLD3R:FRNT=Y!&QQ+YJQNEQ"`=XR[*0T[5
M$,MP%;,,1E#BH2<FJ<[O1K:,M;<K[[HJ>88^EE^'S:,G.*BG4A9:I[R6E[K\
M3ZD_X*O_`/!7S3O^">TN@^'=`T6Q\8_$+7P+O^S9;ADATRQR5$TOEAG9Y'&R
M.,;=VV1MWR`/]!_LB>*OBA\0?A/8:_\`%;0_#?A+Q#JJ+,NA:69I9-+C/(2X
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MR1V:8V_FD#C,AQQ7T37'?`/X+:!^SK\'?#?@;PO`UOH'A2PBTZR1V#2,B(!O
M<@#,CG+L<#<S$XYKL:X,74IU*]2=)6BY-I>3>AZ&#IU(8>G3K.\E%)ON[:L*
M***YSI"D?E#@X..OI2T4`?%/[;?_``0S^#G[7U_J&O6%M-\.O&]T6EEU;084
M6WOY"<[[JSXCE8GDNACD8X+.<`#YY^`_PG_;-_X)%1)H^FZ!I_[0WP<L69UT
MW2;HC4M+C).3:Q2#[1$2>?L\:W$7)"A"S/7ZN4$<&O=H<0XN-#ZI7M5I?RSU
MM_A>C7R9X-?AW"RK?6J%Z57^:&E_5:I_<?-'[-W_``5=^#O[1VNQ^'_[<NO`
M?CI2J3>$?&5N=$UF)R>%6.8A9B>H\IG.,Y`(('TF2TL#AAL.,>O:N6^+7P0\
M'?'70UTOQKX4\,^+],4[A9ZYI<&HVX/J(YE9<^X&:Y7_`(8_\(:,EF/#3^)/
M`Z:>FRSM?#6NW>FZ;:<8&W3DD^PG''#P,..01D5Y=9X64KTDX)]'[R^_1_@_
M4]&C]9A&U1J;75>Z_NU7XKT/SG_X*M_\$W/B/^SC^TU_PTY^SPE])J"W3:MK
MFF:7;B6]TR[(Q->10`'[3;SJ6$\(#,&D=]K)(S0=)^S;_P`'-WP_\0>$K:+X
MH^#_`!#X>UZ(!+B\T")-0TVY<#!<(\BSQ$D$;"),8QYC=:_1C0_!/B7PTHC'
MC"36H?O,^KZ7`]SGN%:V\B,#ZQ,<D\GI7,>,OV(_@]\7M?GUWQ=\(OA=X@UZ
M[.;B^U'PS97UQ*1T)FDAWM^.<5]#'/,+7P\</F=+VG(K1G%\LDNSNM?(^<ED
M6*H8B6(RNK[-3=Y0DN:+?=6V/F`?\''W[-V?^/CQX/\`N7'/\FS^5?$'_!%7
MX::+^UC\?_VFO"][/)#H7Q!\&ZG;+<^5^^M8[J_`2;:W1TRK@'H5%?K0?^";
MO[/9!S\"_@YCW\%Z;_\`&:Z'X6_L=_"?X(^*AKG@KX9^`?!^L&%K9K[1/#]K
MIUP\+%6:(R0QJQ0E$)7."5'H*UIYWEV&PU:C@*<XRJ)*\I)VL[K8BIDF8XK%
M4:V.J0E&FV[1C)7NK/>Y^17[!?[?7BG_`((H_%#Q-\"_CCX4UJY\-G4&U&TF
MTX"2:R9P%>[M5<HMQ93^6'&Q@R.L@VF1GC7KM)^/?_!-IS=SZ[X8U_Q)K6IW
MMQJ.H:C>Z'J0FN[BXE::1MJ.$50TA"JHPJA1SC)_63XM_`/P/\?-/MK+QSX.
M\*^,K&RD\ZVM]<TFWU&*"3^^BS(P5L<9'I7!'_@F]^SXQ/\`Q8KX.^__`!1>
MF_\`QFM9<28&M4>)J4ZE.I+XO9S45)]]5U,EPYCZ4%AJ=2G.G'X54@Y-+MH^
MA\E_`&#]D+]NS]GOXN?`SX#6-GX0U3Q=HOV^[6;1;FVG:2W=/LMV6F!,T=O<
MM"Q0/\N\\#S"Q^;O^"<O_!4;6?\`@DQ?:Q\`?CWX/UZSTSP]?33V4UC$LMSH
MS3.SRJL9*BXLY9/,GCEB8MF5^&!Q'^L'PW_8L^#_`,'/%L&O^#_A7\./"FN6
MR-'%J6C>&K.QO(U;AE66*-6"L.",X(X-;GQ<_9S^'_[0$5DOCOP-X.\:IIA9
M[1=>T6VU(6I888Q^<C;"1P<8S7-#/\)^]PU:G*I1G:7O27.IK[2E;JO(Z7D6
M+_=XBE4C3K0O'W8OD<7]EQ\O4_,[]OW_`(.%?"GQ"^#^H^"/@=IGBC5?$OB^
MW;2AK-WI[VR6"3@Q,+:(9FFNB&*H`H"LP;+D!&^E?^"'7[".K_L1_LC.WBJU
M6P\9^.KT:SJMDP&[2X1$L=O:,02-Z*&=^3M>>1<G:#7T+\-?V-?A%\&_%D.N
M>#OA9\-_"FLPHT::AH_AFSLKQ%;AE$L4:L%(X(SS7I[=#7)C<XPWU/ZCE]-P
M@VG)R=Y2:VO9+1=CJP&3XGZY]?S"JIS2<8I*T8I[VU>K[G\Z/[4?_!-K6/#/
M_!5F?X`^'$O-.T/X@:];ZEH@A.V&WTJX\Z;SU3)#"RB%]$&(+'[/)R-P!_6'
M_@JM_P`$Z!^U'^P18>`OA_8VEIK'PX:WO_"VG+B.&X2UMGM?L&X\*'MW94W$
M+YB1;B`"1]5:E\)O#>L?$;3O%]UX?T2;Q5I%K)8V>L26$+W]I;R,&DACG*^8
MB.1\RJ0#W%=$_P!TX.#BNK'\6XK$SPU5:2H)?.7=^JLCGP/".%H1Q-.6L:S?
MRB^B]'J?D'_P3M_X+X:'\`?A#IOPK^/6A^*M(UWP'&-#AU2"P:60PVX,:P7U
MNY6>*YB5%C8A7WE26V-D'SK_`(*U?\%LM/\`VTOA?=?"WX3Z'XCM_#&H%;O7
M]6U"S,=QJ$%NPF\N&%"S1P`QK(\DA0D)MVA2Q;]=?BC^QW\*/CGKW]K>-/AE
M\//%VK"-81?:UX<L[^Y\M<[4,DJ,VT9.!GC)H\$?L=?"?X::+K.F^&_AC\//
M#^G>([5[#5[73/#=G:PZM;.I5X+A$C`EC8$@JP((X((XKHHY[E%+%1QZPLO:
M7O;G]R_=:?,Y:^19O4PKP+Q4?9VM?D]YKHGK^)\A_P#!O;XIT[P7_P`$M)]7
MUB]L],TO3-?UF[OKNZE6*"RA0J[R2.V`JJHR2>`*^1]:UCQ'_P`'!O\`P4:M
M;&R;4M+^!?P\^=IMC(8-/9\-,>PO;]D"H&&88H\[28I-_P"MEG^Q)\'M,^'E
M[X/MOA7\.;;PCJ=TM]>:%%X;M$TV[N%"@3R6XC$;2`(@WE2<(H[#'1?"CX`^
M!_@%I-QI_@3P=X5\%:?>3_:KBUT+2+?3H;B7:$\QUB50S[0J[B"<*!TK"/$5
M&EBL1CJ--^UJ-\K=K0ONUW?1/0Z)</5JN%P^`K5%[*FESI7O.VR\EW6I^./[
M1'PP\7_\$!?V]-,^)'@*TO-5^#GC2XDMS8/.722%B99](FD8\31$&6VFDR=L
M9!9]L^[]0?@3_P`%(OAG^U#X?@OOAO+XF\;-<)\T>GZ!=I':O@%HIKF:..TA
MD&?N23J3@[=W&?6_B3\+O#GQ?\.OHWBS0-!\3:+(\<K6&KV$5[;/(C;D8QRA
ME)5@"#C@C-;.BZ1;:%ID-G96]O:6ELH2&"",1Q0J.`JJ.`!Z"N+,LYIX^A3>
M(IMUHJSG>W,EM=6>OS.S+,FJ8"M4CAZB5&3NH6NXM[V=]%Y6*-K;W?BC1'74
M(7TMYC@QVUXQE1.#@R*%VL0<$(3C^%SP:F\*^$M.\#Z-%IVDV=II]E$S,L-O
M$(T#,2SM@=69BS%CDDL2222:U#T->4?M$_!;Q'\6-5TYM#\7ZMX5MX;*\M+F
M2POI8)`9XBBRA%PLDL9YC9R!$V6PY("^+!*<N5NR/<J2<(\R5VCU>BN*^!'@
MS7?A_P##JWT[Q+K?_"1:XU[>7MY?J)%A9[F[EN/*A61W=((A*(HHR[;(XD4$
MA17:UF[7:3O8UBVTFU8****"@HHHH`****`"BBB@`HHHH`*I>)-<M?#'AR_U
M*^E%O8Z=;27-Q*>D<:*69OP`)JZW0UY=^V?\,?$GQL_97^(7@SPC=Z38>(O%
M_AZ\T2SN=2DDCM[=KF)H6=FC5G&$=R,*?F`]ZTHQC*I&,W9-ZOL8UYRC3E**
MNTG8^;?"_P#P69TWQ;^R)\+/'EKX5T&3Q]\5O$FG^'[/P-'XOBEN;(WEZ\$<
MTDPAWJ!#&)B#`HS(J9&=]:WPV_X*M2_$/XZ:!X6C\`16WA[Q%\3_`!'\-;77
MAKY?S&TFT$Z7B0_9P&6XE$L03S/D\LMN?.VL2;_@D3H?@SXF?LX:MX*\-?#'
M1H/A");OQ/J$>F)8ZSXGOH-.6&P=IX8"TJFZ#2S>:P/(8!FXKBO$O_!);XGP
M_P#!/#X._#KPOXW\+:+\5?`7B>Z\1:IXHW3M$SWD>HK<R6[>5O:5?MD.PLL?
M^ISE2!7TRIY+)6B[<S:UO[J?-9NS^S9>O,?+3K9Q"[:ORI/2WO-<MTM-W=^G
M*>NV'_!32[\;^`_$?B'POX'M[S2KGXAVGPW\`W-QK#*OC>[:Y$%Y=JJP$0VM
MOMNI`ZM(9$LYB?+(`K6^-/\`P4QTCX3?MP^"_@Q9>&Y]?AUR_L]*\1>(4U#R
M;7PQ>WT4\VFVC((V\V:X2VE;9NCVH8FRV\`2:?\`L67?PU\<_"FV\'V_AV'X
M??`?P=J,'A/3+V\F2:\\03Q+:0W-WLA*")+7[2&E4M(SW\S>6,#=X5:_\$8_
M&]CX2\+^*)OBQJ>M?%B'X@Z=\2?$=M>7*1^%;[5(KE7GDAC2T^T92`>3$68#
M"`;8U;:.>A3RJ<W*;LG>RUOKLWVLDI/SEV.BO/-(0Y*2O)6N]+66Z7>[;BO*
M)Z%\;/\`@K1=_#/QM\4-#T3X<+XGO_!7C7P[\/\`P]N\1?8U\6:OJL)DE@_X
M]G%L;<#'/F[\@_)6EHG_``53U#P/=_%C0_BY\*M4^'_BWX7^$&\<_P!FZ9K"
M>((==TD%X_.MYXXH]I$J[&$B*J\L6VHY7R7Q!_P3$^->E-HNL:!J_P`*M1\0
M0?&76_B]JEMK5Y?C3IKN8+'IL:^5!O;R(PY.0N'`"D@DUW4?[`?QTU-O'_Q.
MG^+_`(7T;]H#Q=#I^G6-WIFA&;PYHFD6DC2'2XX[CS)6BN'??+*1N#!<*0&W
M[.CE2IQ2<=;:WE>_NKS23LVW;2ZL<_M\TYV[2TOI:-K.[OT=TVDE?6VIW/[%
MO[<?Q`_:7\5:0VO?"W1-+\'^*M$.LZ;XD\,>+T\1V-E(#$?L%\PAB\FY*N2-
MNY<J5ZBO6/$7[:'PR\(KXH;4?&&E6Q\%ZO:>']94B5I+/4+ORC;6NP(6>23S
MH]JH&^][''@7[#_[`GBSX)_M;^*/BWXETOX2?#T:QX9B\.?\(O\`#=;I=*OY
MA<I.^I7(FBA7SQLV($B.$D?+DY+&H?\`!-7Q!XI_X*1>*?BUJ?B#0SX%NKFS
M\3Z-HB0-/.GB6UTJ/3+>\N590K1V\?G/&JN"9)%)QMYXJ^'R^>(DHR48**:M
MU:^SK?7SV_([L/7S"&'BY1<IN33OT3^UI;3RW/;?"G[?WP?\;_&-O`>D^.M'
MO/$_VB[M$MU698;F>T4M=0PW#1B":6%58R)'(S(%8L!M-4/`'_!2?X&?%*\U
M^'0?B;X5N_\`A&=.EUG49I+AK:!+")Q'+>1RR*J36Z.0IEB9D!8#=DBOD?PM
M_P`$C?BYX\N=*_X65XWT5I=,\'>*=$?5+;Q-J^L&YU75[*2R34XK&=(;.Q58
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M(8+J[@2&:VE2WGW>3<*DR(TD$@5BDR`QN!\K&OB3X(?\$??B!X'\&V.D:RWP
MLO)?`WA34M"\+RWVO>*->L-1O+RVDM)II].N+B.RL;>>VDFCF@MHY,M,7#Y5
M5KZ"_P"";W['OC?]E._\8MXFU73;;P[K']G0>&_"NG^(]1\26OAF.!)1.(;Z
M_CCG\J:1U86^W9#L.&8L366.P>6TZ<WAZK<EM>VNMNW56:[7M?377`XS,:E6
M$:U)*+O>U]-$[;]'=/O:]M3ZNHHHKQ#WPHHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`,4444`&****`#%&***`#%&***`"C%%%`!1BBB@`P*,444`%%%%
,`!1110`4444`?__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
